Kurs
+3,21%
Likviditet
79,4 MDKK
Kalender
| Est. tid* | ||
| 2026-11-12 | 07:00 | Kvartalsrapport 2026-Q3 |
| 2026-08-13 | 07:00 | Kvartalsrapport 2026-Q2 |
| 2026-05-26 | N/A | Extra Bolagsstämma 2026 |
| 2026-05-07 | 07:00 | Kvartalsrapport 2026-Q1 |
| 2026-03-30 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2026-02-19 | - | Bokslutskommuniké 2025 |
| 2025-11-13 | - | Kvartalsrapport 2025-Q3 |
| 2025-08-14 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-08 | - | Kvartalsrapport 2025-Q1 |
| 2025-03-28 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2025-03-27 | - | Årsstämma |
| 2025-02-20 | - | Bokslutskommuniké 2024 |
| 2024-11-07 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-15 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-16 | - | Kvartalsrapport 2024-Q1 |
| 2024-03-21 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2024-03-20 | - | Årsstämma |
| 2024-02-27 | - | Bokslutskommuniké 2023 |
| 2023-11-09 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-17 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-11 | - | Kvartalsrapport 2023-Q1 |
| 2023-03-30 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2023-03-29 | - | Årsstämma |
| 2023-03-02 | - | Bokslutskommuniké 2022 |
| 2022-11-10 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-11 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-12 | - | Kvartalsrapport 2022-Q1 |
| 2022-05-09 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2022-04-06 | - | Årsstämma |
| 2022-03-10 | - | Bokslutskommuniké 2021 |
| 2021-11-11 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-12 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-12 | - | Kvartalsrapport 2021-Q1 |
| 2021-04-16 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2021-04-15 | - | Årsstämma |
| 2021-03-11 | - | Bokslutskommuniké 2020 |
| 2020-11-12 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-13 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-14 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-03 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2020-04-02 | - | Årsstämma |
| 2020-03-12 | - | Bokslutskommuniké 2019 |
| 2019-11-14 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-15 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-16 | - | Kvartalsrapport 2019-Q1 |
| 2019-04-05 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2019-04-04 | - | Årsstämma |
| 2019-03-07 | - | Bokslutskommuniké 2018 |
| 2018-11-15 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-16 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-16 | - | Kvartalsrapport 2018-Q1 |
| 2018-04-20 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2018-04-19 | - | Årsstämma |
| 2018-03-07 | - | Bokslutskommuniké 2017 |
| 2017-11-08 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-24 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-17 | - | Kvartalsrapport 2017-Q1 |
| 2017-04-06 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2017-04-05 | - | Årsstämma |
| 2017-03-15 | - | Bokslutskommuniké 2016 |
| 2016-11-09 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-25 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-18 | - | Kvartalsrapport 2016-Q1 |
| 2016-04-20 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2016-04-19 | - | Årsstämma |
| 2016-03-16 | - | Bokslutskommuniké 2015 |
| 2015-11-05 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-28 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-22 | - | Kvartalsrapport 2015-Q1 |
| 2015-04-22 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2015-04-21 | - | Årsstämma |
| 2015-03-12 | - | Bokslutskommuniké 2014 |
| 2014-11-07 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-21 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-06 | - | Kapitalmarknadsdag 2014 |
| 2014-04-29 | - | Årsstämma |
| 2014-04-29 | - | Kvartalsrapport 2014-Q1 |
| 2014-03-21 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2014-03-20 | - | Bokslutskommuniké 2013 |
| 2013-11-15 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-29 | - | Kvartalsrapport 2013-Q2 |
| 2013-05-15 | - | Kvartalsrapport 2013-Q1 |
| 2013-04-30 | - | Årsstämma |
| 2013-04-30 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2013-03-14 | - | Bokslutskommuniké 2012 |
| 2012-11-29 | - | Kapitalmarknadsdag 2012 |
| 2012-04-26 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2012-04-25 | - | Årsstämma |
| 2011-11-17 | - | Kvartalsrapport 2011-Q3 |
| 2011-10-25 | - | Kapitalmarknadsdag 2011 |
| 2011-08-18 | - | Kvartalsrapport 2011-Q2 |
| 2011-05-12 | - | Kvartalsrapport 2011-Q1 |
| 2011-04-29 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2011-04-28 | - | Årsstämma |
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Large Cap Copenhagen |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Press Release – No. 8 / 2026
Zealand Pharma conference call on May 7 at 2pm CET (8am ET) to present first quarter 2026 financial results
Copenhagen, Denmark and Boston, Massachusetts, April 30, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, announced that it will host a conference call on May 7, 2026, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the first quarter / first three months of 2026.
Participating in the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; and Chief Medical Officer, David Kendall. The presentation will be followed by a Q&A session.
To receive telephone dial-in information and a unique personal access PIN, please register at Conference Registration. The live listen-only audio webcast of the call and accompanying slides presentation will be accessible at Zealand Pharma results for Q1 2026. Participants are advised to register for the call or webcast approximately 10 minutes before the start. A recording of the event will be available following the call on the Investor section of Zealand Pharma’s website at https://www.zealandpharma.com/events/.
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data‑driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health.
To date, more than ten Zealand Pharma‑invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization.
Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com.
Contacts
Eric Rojas (Investors)
Vice President, Head of Investor Relations
erojas@zealandpharma.com
Adam Lange (Investors)
Vice President, Investor Relations
alange@zealandpharma.com
Neshat Ahmadi (Investors)
Investor Relations Manager
neahmadi@zealandpharma.com
Rachel James-Owens (Media)
Vice President, Corporate Communications & Media Relations
Zealand Pharma
Email: RJamesOwens@zealandpharma.com
Andreas Hylleberg (Media)
Director, External Communications
Zealand Pharma
Email: AHylleberg@zealandpharma.com
Amber Fennell, Jessica Hodgson, Sean Leous (Media)
ICR Healthcare
Email: ZealandPharma@icrhealthcare.com
+44 (0) 7739 658 783